Premium
Determination of fluoxetine in pharmaceutical and biological samples based on the silver nanoparticle enhanced fluorescence of fluoxetine–terbium complex
Author(s) -
Lotfi Ali,
Manzoori Jamshid L.
Publication year - 2016
Publication title -
luminescence
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.428
H-Index - 45
eISSN - 1522-7243
pISSN - 1522-7235
DOI - 10.1002/bio.3114
Subject(s) - terbium , fluoxetine , chemistry , silver nanoparticle , fluorescence , detection limit , nuclear chemistry , nanoparticle , analytical chemistry (journal) , chromatography , materials science , nanotechnology , ion , organic chemistry , biochemistry , receptor , physics , quantum mechanics , serotonin
Abstract In this study, a simple and sensitive spectrofluorimetric method is presented for the determination of fluoxetine based on the enhancing effect of silver nanoparticles (AgNPs) on the terbium–fluoxetine fluorescence emission. The AgNPs were prepared by a simple reduction method and characterized by UV–Vis spectroscopy and transmission electron microscopy. It was indicated that these AgNPs have a remarkable amplifying effect on the terbium‐sensitized fluorescence of fluoxetine. The effects of various parameters such as AgNP and Tb 3+ concentration and the pH of the media were investigated. Under obtained optimal conditions, the fluorescence intensity of the terbium–fluoxetine–AgNP system was enhanced linearly by increasing the concentration of fluoxetine in the range of 0.008 to 19 mg/L. The limit of detection ( b + 3 s ) was 8.3 × 10 ‐4 mg/L. The interference effects of common species found in real samples were also studied. The method had good linearity, recovery, reproducibility and sensitivity, and was satisfactorily applied for the determination of fluoxetine in tablet formulations, human urine and plasma samples. Copyright © 2016 John Wiley & Sons, Ltd.